Harnessing Pol Theta Inhibition as a Cancer Specific DDR Target to Overcome Resistance in PARPi-Resistant Cancers
Time: 11:00 am
day: Day One
Details:
- Discussing the mechanistic role of pol theta in DNA double-strand break (DSB) repair and DNA damage tolerance through translesion synthesis, with potential to address resistance in PARPi-resistant cancers and enhance the efficacy of DNA-damaging agents like chemotherapy and ionizing radiation
- Examining how pol theta inhibitors offer the potential to selectively target tumor cells while sparing normal tissue from toxicity, enabling safer and more effective combination therapies with PARP inhibitors in homologous recombination-deficient cancers
- Exploring genotoxic stress as a biomarker for patient stratification in pol theta combination therapies, highlighting the inhibitor’s promise in expanding therapeutic options and addressing unmet needs in oncology
